Hala Fadda

Dr. Hala Fadda

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

31 March 2016 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
MFMonika Fischer
Monika Fischer
SSShivi Siva
Shivi Siva
JWJohn M. Wo
John M. Wo
HFHala Fadda
Hala Fadda

6 September 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
HFHala Fadda
Hala Fadda
HWHannah Weiler
Hannah Weiler
Maria CarvalhoMaria Carvalho
Maria Carvalho
YLYou Zhuan Lee
You Zhuan Lee
HDHadi Dassouki
Hadi Dassouki
GPGiovanni M. Pauletti
Giovanni M. Pauletti

1 February 2016 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
MFMonika Fischer
Monika Fischer
HFHala Fadda
Hala Fadda

1 June 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AAA. Aburub
A. Aburub
MFM. Fischer
M. Fischer
MCM. Camilleri
M. Camilleri
JSJ.R. Semler
J.R. Semler
HFHala Fadda
Hala Fadda

1 April 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
SASahar Awwad
Sahar Awwad
RDRichard M. Day
Richard M. Day
PKPeng T. Khaw
Peng T. Khaw
SBSteve Brocchini
Steve Brocchini
HFHala Fadda
Hala Fadda
Corticosteroids have long been used to treat intraocular inflammation by intravitreal injection. We describe dexamethasone loaded poly-DL-lactide-co-glycolide (PLGA) microparticles that were fabricated by thermally induced phase separation (TIPS). The dexamethasone loaded microparticles were evaluated using a two-compartment, in vitro aqueous outflow model of the eye (PK-Eye) that estimates drug clearance time from the back of the eye via aqueous outflow by the anterior route. A dexamethasone dose of 0.20±0.02mg in a 50μL volume of TIPS microparticles resulted in a clearance t1/2 of 9.6±0.3days using simulated vitreous in the PK-Eye. Since corticosteroids can also clear through the retina, it is necessary to account for clearance through the back of the eye. Retinal permeability data, published human ocular pharmacokinetics (PK) and the PK-Eye clearance times were then used to establish in vitro in vivo correlations (IVIVCs) for intraocular clearance times of corticosteroid formulations. A t1/2 of 48h was estimated for the dexamethasone-TIPS microparticles, which is almost 9 times longer than that reported for dexamethasone suspension in humans. The prediction of human clearance times of permeable molecules from the vitreous compartment can be determined by accounting for drug retinal permeation and determining the experimental clearance via the anterior aqueous outflow pathway using the PK-Eye.